Who is sponsoring NCT03201172?

NCT03201172 is sponsored by Aesculap AG.

What drugs are being tested in NCT03201172?

Interventions in NCT03201172: Primary Unicompartmental Knee Arthroplasty.

What condition does NCT03201172 study?

NCT03201172 studies Unicompartmental Knee Arthroplasty.

Is NCT03201172 still recruiting?

NCT03201172 is currently completed. Last updated 15 April 2021.

Last reviewed 2021-04-15 · How we verify

NCT03201172

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Univation® X Follow-Up Study

Completed Last updated 15 April 2021

What this trial tests

trial testing Primary Unicompartmental Knee Arthroplasty in Unicompartmental Knee Arthroplasty in 77 participants. Completed in 1 April 2020.

Timeline

25 September 2017

Primary endpoint
30 September 2019

1 April 2020

Quick facts

Lead sponsor	Aesculap AG
Status	Completed
Study type	OBSERVATIONAL
Enrollment	77
Start date	25 September 2017
Primary completion	30 September 2019
Estimated completion	1 April 2020
Sites	1 location across Germany

Drugs / interventions tested

Primary Unicompartmental Knee Arthroplasty

Conditions studied

Unicompartmental Knee Arthroplasty — all drugs for Unicompartmental Knee Arthroplasty →

Sponsor

Aesculap AG — full company profile →

Who can join

18 and older, any sex, with Unicompartmental Knee Arthroplasty. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study is designed as a monocentric, prospective, observational, comparative follow-up study based on two previously treated patient groups. The first group consists of patients treated with the patient-specific unicondylar knee implant iUni®. For that group, 30 patients will be included in the study and analyzed. The final follow-up after 24 months has already been documented by the study center. Compared to that, a consecutive series of 50 Univation® X patients will be invited for a 24 months follow-up in 2018. In total, it is planned to include 80 retrospective patients for that historical control study design. The products under investigation were used in routine clinical practice and according to the authorized Instructions for Use (IfU). Those data that are obtained in routine clinical use will be documented in the Case Report Form (CRF).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

No advantage for patient-specific UKA in comparison with standard UKA regarding clinical and functional results at short-term follow-up.
Haaker R, Moussa A, Sabev D. · · 2025 · cited 1× · PMID 40866508 · DOI 10.1007/s00590-025-04467-2

Verify or expand the search:

Other recruiting trials for Unicompartmental Knee Arthroplasty

Currently open trials in the same condition.

NCT05735847 — Surgery Induced Trauma After Total Versus Medial Unicompartmental Knee Arthroplasty (SITA) · active not recruiting
NCT05876143 — Ambispective Multicentric Study Evaluating UKA With U-Knee/Uni-Kroma Implants · recruiting

Other Aesculap AG trials

Trials by the same sponsor.

NCT05441618 — Post Market Clinical Follow-Up Study on the Performance and Safety of Lyoplant® · completed
NCT05944081 — Postmarket Clinical Follow-Up Study on Arcadius XP L® Interbody Fusion Device · withdrawn
NCT06298500 — Clinical Performance of HISTOACRYL® LAPFIX - CANNULA for Laparoscopic Inguinal Hernia Repair · completed
NCT06055946 — Symmcora® Long-term Bidirectional Barbed Suture for Anastomosis in Patients Undergoing Robot Assisted Radical Prostatect · completed
NCT05182320 — Study Measuring the Effects of Patient Data for Total Hip and Total Knee Arthroplasty Patients Using an APP Based Sensor · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03201172 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aesculap AG
Last refreshed: 15 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03201172.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing